Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery
A Before/After Study of the Impact of Quantitative Neuromuscular Monitoring and Sugammadex Reversal Following Gastric Bypass Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ana P Arias, BS
- Phone Number: 916-703-5456
- Email: apaarias@ucdavis.edu
Study Contact Backup
- Name: Julio J Arana Pineda, BA
- Phone Number: 916-734-4074
- Email: jjaranapineda@ucdavis.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Medical Center
-
Contact:
- Neal Fleming, MD, PhD
- Phone Number: 916 734-5046
- Email: nwfleming@ucdavis.edu
-
Contact:
- Ana Arias
- Phone Number: 916-703-5456
- Email: apaarias@ucdavis.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age greater than 18 years
- scheduled for an elective laparoscopic gastric bypass procedure
Exclusion Criteria:
- age less than 18 years
- pregnancy
- prisoners
- significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
- patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2>98%)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxygen desaturation
Time Frame: 24 hours
|
Incidence and magnitude of significant oxygen desaturation
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative unit length of stay
Time Frame: 7 days
|
Length of stay (Hours)
|
7 days
|
|
Hospital Length of stay
Time Frame: 7 days
|
Length of stay (Hours)
|
7 days
|
|
The rate of compliance with muscle relaxant monitoring and reversal protocols
Time Frame: 24 hours
|
Rate of compliance (%)
|
24 hours
|
|
Total intraoperative rocuronium use
Time Frame: 24 hours
|
Total dose/kg/hr (mg/kg/hr)
|
24 hours
|
|
Total sugammadex dose
Time Frame: 24 hours
|
Total dose (mg/kg)
|
24 hours
|
|
Post-operative supplemental oxygen requirement
Time Frame: 24 hours
|
Oxygen requirement (FiO2%/hr)
|
24 hours
|
|
Success rate for wearable device
Time Frame: 24 hours
|
Rate of compliance (%)
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2004503
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.